EUVIMEDEUVIMED entdecken
Crossref

Chicoric acid acts as an ALOX15 inhibitor to prevent ferroptosis in asthma

Lianxiang Luo, Kangdi Liu, Liyan Deng, Wenjian Wang, Tianli Lai, Xiaoling Li

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.113187 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Lianxiang Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine. Guangdong Medical University, Zhanjiang, Guan…. Hauptthemen laut MEDLINE: Asthma, Ferroptosis, Caffeic Acids, Arachidonate 15-Lipoxygenase. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province, Guangdong Medical University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chicoric acid (CA) is a crucial immunologically active compound found in chicory and echinacea, possessing a range of biological activities. Ferroptosis, a type of iron-dependent cell death induced by lipid peroxidation, plays a key role in the development and advancement of asthma. Targeting ferroptosis could be a potential therapeutic strategy for treating asthma. PURPOSE: The purpose of this study was to explore the screening of ALOX15, a pivotal target of ferroptosis in asthma, and potential therapeutic agents, as well as to investigate the promising potential of CA as an ALOX15 inhibitor for modulating ferroptosis in asthma. METHODS: Through high-throughput data processing of bronchial epithelial RNA from asthma patients using bioinformatics and machine learning, the key target of ferroptosis in asthma, ALOX15, was identified. An inhibitor of ALOX15 was then obtained through high-throughput molecular docking and molecular dynamics simulation tests. In vitro experiments were conducted using a 16HBE cell model induced by house dust mite (HDM) and lipopolysaccharide (LPS), which were treated with the ALOX15 inhibitor (PD146176), CA treatment, or ALOX15 knockdown. In vivo experiments were also carried out using a mouse model induced by HDM and LPS. RESULTS: The composite model of ALOX15 and CA in molecular dynamics simulations shows good stability and flexibility. Network pharmacological analysis reveals that CA regulates ferroptosis through ALOX15 in treating asthma. In vitro studies show that ALOX15 is highly expressed in HDM and LPS treatments, while CA inhibits HDM and LPS-induced ferroptosis in 16HBE cells by reducing ALOX15 expression. Knockdown of ALOX15 has the opposite effect. Metabolomics analysis identifies key compounds associated with ferroptosis, including L-Targinine, eicosapentaenoic acid, 16-hydroxy hexadecanoic acid, and succinic acid. In vivo experiments demonstrate that CA suppresses ALOX15 expression, inhibits ferroptosis, and improves asthma symptoms in mice. CONCLUSION: Our research initially identified CA as a promising asthma treatment that effectively blocks ferroptosis by specifically targeting ALOX15. This study not only highlights CA as a potential therapeutic agent for asthma but also introduces novel targets and treatment options for this condition, along with innovative approaches for utilizing natural compounds to target diseases associated with ferroptosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaFerroptosisCaffeic AcidsArachidonate 15-LipoxygenaseSuccinatesAnimalsHumansMiceCell LineMice, Inbred BALB CLipopolysaccharidesFemaleMolecular Docking SimulationPyroglyphidaeDisease Models, AnimalLipoxygenase InhibitorsAnti-Asthmatic AgentsMaleArachidonate 12-Lipoxygenase

Stichwörter der Autor:innen

ALOX15AsthmaChicoric acid (CA)FerroptosisFerroptosis inhibitor

Substanzen

Caffeic Acidschicoric acidArachidonate 15-LipoxygenaseSuccinatesALOX15 protein, humanLipopolysaccharidesLipoxygenase InhibitorsAnti-Asthmatic AgentsAlox15 protein, mouseArachidonate 12-Lipoxygenase

Autor:innen und Institutionen

  • The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine. Guangdong Medical University, Zhanjiang, Guangdong 524023, China. Electronic address: luolianxiang321@gdmu.edu.cn.
  • The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine. Guangdong Medical University, Zhanjiang, Guangdong 524023, China.
  • Experimental Animal Center, Guangdong Medical University, Zhanjiang 524023, Guangdong, China.

Förderung

  • Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province
  • Guangdong Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Luo, L., Liu, K., Deng, L., Wang, W., Lai, T., & Li, X. (2024). Chicoric acid acts as an ALOX15 inhibitor to prevent ferroptosis in asthma. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113187

Vancouver

Luo L, Liu K, Deng L, Wang W, Lai T, Li X. Chicoric acid acts as an ALOX15 inhibitor to prevent ferroptosis in asthma. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113187

BibTeX
@article{Luo2024,
  author = {Luo, Lianxiang and Liu, Kangdi and Deng, Liyan and Wang, Wenjian and Lai, Tianli and Li, Xiaoling},
  title = {Chicoric acid acts as an ALOX15 inhibitor to prevent ferroptosis in asthma},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.113187}
}
Kostenlos starten →